迪哲医药(688192) - 迪哲医药投资者关系活动记录表

Group 1: Financial Performance - The company achieved a sales revenue of 338 million yuan in the first three quarters of 2024, representing a year-on-year increase of 744% [3] - The sales growth is attributed to the performance of Shuwozhe® and Gaoruizhe® [2] Group 2: Product Information - Shuwozhe® is the only approved targeted therapy for NSCLC with EGFR Exon 20 insertion mutations, launched in August 2023 [3] - Gaoruizhe® was approved in June 2024 for the treatment of relapsed/refractory peripheral T-cell lymphoma (PTCL), with an objective response rate (ORR) of 44.3% and a complete response (CR) rate of 23.9% [3] Group 3: Market Strategy and Regulatory Engagement - The company is actively participating in national medical insurance negotiations for its products, which is expected to support the development of innovative drugs in the industry [4] - Ongoing global registration clinical studies for Shuwozhe® are progressing, with significant data expected to support overseas market applications [4][5]